Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension (ARTISAN)
The purpose of this trial is to test how well the iCAST™ RX Stent works in patients diagnosed with atherosclerotic renal artery stenosis and whether or not increased blood flow by the stent will help to control blood pressure.
Renal Artery Stenosis
Device: iCAST™ Rx Stent System
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||ARTISAN: iCAST™ RX De Novo Stent Placement for the Treatment of Atherosclerotic Renal Artery Stenosis in Patients With Resistant Hypertension|
- Functional Endpoint: Primary Patency [ Time Frame: 9-Months ] [ Designated as safety issue: No ]Assessment of primary patency rate at 9-months, defined as continuous patency without the occurrence of a total occlusion of the original lesion, without a re-intervention to treat a partial or total occlusion of the stented segment, or bypass of the stented segment due to clinically-driven restenosis or occlusion.
- Clinical Endpoint: Systolic Blood Pressure Improvement [ Time Frame: 9-Months ] [ Designated as safety issue: No ]Improvement in systolic blood pressure (SBP) at 9-months as compared to baseline systolic blood pressure.
- Procedure-Related Major Adverse Events (MAE) [ Time Frame: 30-Days, 9-Months, 12-Months, 24-Months, and 36-Months ] [ Designated as safety issue: Yes ]
The occurence of procedure-related MAEs reported as a percentage of subjects with MAE. Inclusive of:
- Procedure- or device-related occurrence of death
- Q-Wave Myocardial Infarction (MI)
- Clinically driven Target Lesion Revascularization (TLR)
- Significant embolic events defined as: unanticipated kidney/bowel infarct clinically driven by symptoms of abdominal or back pain and confirmed with CT scan or open surgery, lower extremity ulceration or gangrene, or kidney failure.
- Technical Success [ Time Frame: Day of Procedure ] [ Designated as safety issue: No ]Defined as successful delivery and deployment of the iCAST™ RX Stent System with ≤ 30% residual angiographic stenosis after covered stent deployment (including post-dilatation) assessed via quantitative vascular analysis (QVA) by an independent core laboratory.
- Procedural Success [ Time Frame: Day of Procedure, prior to hospital discharge ] [ Designated as safety issue: No ]Defined as technical success without the occurrence of MAE prior to hospital discharge.
- Target Lesion Revascularization (TLR) [ Time Frame: 9-Months ] [ Designated as safety issue: No ]
Measured as the proportion of subjects that require a clinically-driven reintervention of the target lesion through 9-months.
a. A clinically-driven TLR is defined as a TLR (percutaneous balloon angioplasty (PTA), bare metal stent or repeat covered stent deployment, or surgical bypass) due to documented recurrent hypertension from 30-days post-procedure level and/or deterioration in renal function from baseline value, associated with angiographic core laboratory adjudication of a ≥ 60% diameter covered stent restenosis.
- Rate of Incidental TLR [ Time Frame: 9-Months ] [ Designated as safety issue: No ]Defined as rate of TLRs not meeting the definition of a clinically driven TLR.
- Improved Systolic Blood Pressure (SBP) Control [ Time Frame: 30-Days, 9-Months, 12-Months, 24-Months, and 36-Months ] [ Designated as safety issue: No ]Improved SBP control assessed at 30-days, 9-months, 12-months, 24-months and 36-months.
- Secondary Patency Rate [ Time Frame: 9-Months ] [ Designated as safety issue: No ]Secondary patency rate at 9-months after a clinically-driven TLR which restores patency after total occlusion.
- Change in Number and Dosage of Anti-Hypertensive Medications [ Time Frame: Baseline to 36-Months ] [ Designated as safety issue: No ]Change in number and dosage of anti-hypertensive medications as compared to baseline.
- Change in Renal Function [ Time Frame: Baseline to 30-Days and Baseline to 9-Months ] [ Designated as safety issue: No ]Renal function compared to baseline as measured by estimated Glomerular Filtration Rate (eGFR) at 30-days and 9-months.
|Study Start Date:||October 2012|
|Estimated Study Completion Date:||December 2017|
|Estimated Primary Completion Date:||June 2015 (Final data collection date for primary outcome measure)|
Experimental: iCAST RX™ Stent Systen
All enrolled subjects will receive the iCAST RX™ Stent System
Device: iCAST™ Rx Stent System
All enrolled subjects will undergo primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.
Other Name: iCAST™ RX
This is a prospective, single-arm, multicenter clinical trial that will take place at up to 25 US/ Outside US (OUS) sites. Primary endpoints have been determined to show the safety, effectiveness, and clinical outcomes of the iCAST™ RX Stent System. Safety and effectiveness will be evaluated based on the primary patency rate at 9-months on a per lesion basis evaluated against a performance goal of published studies with bare-metal stents. The primary clinical endpoint will assess the improvement in Systolic Blood Pressure (SBP) at 9-months as compared to baseline Systolic Blood Pressure.
Eligible subjects will undergo a two-week Medical Documentation Screening period to confirm resistant hypertension (SBP ≥ 155mmHg) while on maximum tolerable doses of ≥ three anti-hypertensive medications from at least three distinct classes of drugs, one of which must be a diuretic.
There must be documented clinical evidence to support likelihood of angiographic findings > 80% whether it is Duplex Ultrasound (DUS), Computed Tomography angiogram (CTa), Magnetic Resonance angiogram (MRa) or other medical evidence. After meeting screening and clinical eligibility criteria, subjects will undergo a baseline assessment for angiographic eligibility. After angiographic documentation of a ≥ 80% renal artery stenosis or Fraction Flow Reserve (FFR) < 0.8 is confirmed, the subject may be enrolled in the trial by placement of the investigational device.
The 9-month visit will include a follow-up DUS of the target renal artery. If the DUS is non-diagnostic due to an imaging problem, such as overlying bowel gas or body habitus, a second DUS may be attempted. If the DUS is indicative of ≥ 60% stenosis as determined by the core laboratory, or the second DUS remains non-diagnostic, a contrast angiogram will be used to assess the degree of restenosis of the covered stent(s).
Clinical follow-up visits will be required for all enrolled subjects at 30-days, 9-months, 12-months, 24-months, and 36-months. A 6-month and 18-month visit will occur via telephone to collect medication usage and Adverse Events (AEs) only. The 36-month clinic office visit will be required as the final safety visit.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01673373
|Contact: Melissa Hitchcock||603-880-1433 ext firstname.lastname@example.org|
|Contact: Kristen Lang||603-880-1433 ext 5372|
Hide Study Locations
|United States, Arizona|
|Arizona Heart Institute||Withdrawn|
|Phoenix, Arizona, United States, 85006|
|United States, California|
|Mission Cardiovascular Research Institute||Recruiting|
|Fremont, California, United States, 94538|
|Contact: Jimmin Chang 510-796-0222 email@example.com|
|Principal Investigator: Ash Jain, MD|
|Radiological Associates of Sacramento||Withdrawn|
|Sacramento, California, United States, 95815|
|United States, Colorado|
|Medical Center of the Rockies||Recruiting|
|Loveland, Colorado, United States, 80538|
|Contact: Scott Kaczkowski 970-624-1685 Scott.Kaczkowski@uchealth.org|
|Principal Investigator: William Miller, MD|
|United States, District of Columbia|
|Howard University Hospital||Withdrawn|
|Washington, District of Columbia, United States, 20060|
|United States, Florida|
|Clearwater Cardiovascular and Interventional Consultants||Recruiting|
|Clearwater, Florida, United States, 33756|
|Contact: Amy Davidson 727-467-9393 DavidsonA@cccheart.com|
|Principal Investigator: Saihari Sadanandan, MD|
|Baptist Cardiac and Vascular Institute||Withdrawn|
|Miami, Florida, United States, 33176|
|United States, Illinois|
|Advocate Health and Hospitals Corporation||Recruiting|
|Naperville, Illinois, United States, 60563|
|Contact: Kim Paprockas 630-873-3404 firstname.lastname@example.org|
|Contact: Alice Szydlowska 630-268-9609 email@example.com|
|Principal Investigator: Mark Goodwin, MD|
|United States, Louisiana|
|Cardiovascular Institute of the South||Withdrawn|
|Houma, Louisiana, United States, 70360|
|United States, Massachusetts|
|Massachusetts General Hospital||Recruiting|
|Boston, Massachusetts, United States, 02114|
|Contact: Hollie Kirwan 617-643-1372 firstname.lastname@example.org|
|Principal Investigator: Douglas Drachman, MD|
|United States, Michigan|
|Beaumont Health Systems||Recruiting|
|Royal Oak, Michigan, United States, 48073|
|Contact: Dorothy Richardson 248-898-9161 email@example.com|
|Principal Investigator: Amr Abbas, MD|
|Michigan Cardiovascular Institute||Recruiting|
|Saginaw, Michigan, United States, 48601|
|Contact: Tacey Gauthier 989-907-8031 firstname.lastname@example.org|
|Principal Investigator: Vipin Khetarpal, MD|
|United States, New Jersey|
|Holy Name Medical Center||Recruiting|
|Teaneck, New Jersey, United States, 07666|
|Contact: Yitzchak David email@example.com|
|Principal Investigator: John Rundback, MD|
|United States, New York|
|Mount Sinai Medical Center||Withdrawn|
|New York, New York, United States, 10029|
|United States, North Carolina|
|Mid Carolina Cardiology||Recruiting|
|Charlotte, North Carolina, United States, 28204|
|Contact: Pailing Richards firstname.lastname@example.org|
|Principal Investigator: Michael Miller, MD|
|Wake Heart and Vascular||Recruiting|
|Raleigh, North Carolina, United States, 27610|
|Contact: Meredith Shillingaw 919-418-8391 email@example.com|
|Principal Investigator: Ravish Sachar, MD|
|United States, Ohio|
|Cleveland, Ohio, United States, 44195|
|University Hospitals Medical Group||Withdrawn|
|Cleveland, Ohio, United States, 44106|
|OhioHealth Research Institute||Recruiting|
|Columbus, Ohio, United States, 43214|
|Contact: Joyce Jackson 614-566-1252 Joyce.Jackson@ohiohealth.com|
|Principal Investigator: Mitchell Silver, DO|
|University of Toledo Medical Center||Withdrawn|
|Toledo, Ohio, United States, 43614|
|United States, Tennessee|
|Wellmont CVA Heart Institute||Recruiting|
|Kingsport, Tennessee, United States, 37660|
|Contact: Brandy Venable, RN 423-230-5643 BVenable@mycva.com|
|Principal Investigator: Christopher Metzger, MD|
|Tennova Healthcare - Turkey Creek Medical Center||Recruiting|
|Knoxville, Tennessee, United States, 37934|
|Contact: Nancy Bradley 865-218-7538 firstname.lastname@example.org|
|Principal Investigator: Malcolm Foster, MD|
|United States, Texas|
|Austin Heart, PLLC||Withdrawn|
|Austin, Texas, United States, 78756|
|The Heart Hospital Baylor Plano||Withdrawn|
|Plano, Texas, United States, 75093|
|United States, Washington|
|Swedish Medical Center||Withdrawn|
|Seattle, Washington, United States, 98122|
|United States, West Virginia|
|CAMC Clinical Trials Center||Withdrawn|
|Charleston, West Virginia, United States, 25304|
|United States, Wisconsin|
|Wheaton Franciscan Medical Group||Withdrawn|
|Racine, Wisconsin, United States, 53405|
|Principal Investigator:||Gary M Ansel, MD||MidOhio Cardiology and Vascular Consultants|
|Principal Investigator:||Kenneth Rosenfield, MD||Massachusetts General Hospital|